AA
ALDR

Apriem Advisors’s Alder Biopharmaceuticals ALDR Stock Holding History

Apriem Advisors’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,230
Closed -$65K – 632
2015
Q2 		$65K Buy
+1,230
New +$44.7K 0.02% 184

Other funds holding ALDR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Apriem Advisors's ALDR Position: Q3 2015 in Review

Apriem Advisors sold out of Alder Biopharmaceuticals (ALDR) in Q3 2015, closing a stake of 1,230 shares — an estimated $65K sold.

Apriem Advisors first reported a position in ALDR in Q2 2015 and held it in 1 quarter. The position peaked at $65K in Q2 2015. 140 funds tracked by Wall St. Rank hold ALDR as of Q3 2015.

  • Apriem Advisors reported no remaining Alder Biopharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Apriem Advisors sold 1,230 Alder Biopharmaceuticals shares in Q3 2015, an estimated $65K.
  • Apriem Advisors first reported a position in Alder Biopharmaceuticals in Q2 2015 and held it in 1 quarter.
  • Apriem Advisors's Alder Biopharmaceuticals position peaked at $65K in Q2 2015.
  • 140 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q3 2015.

Based on Apriem Advisors's 13F filing for Q3 2015, filed 13 Nov 2015.